Terms: = Adult Hodgkin lymphoma AND MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7
1553 results:
1. Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States.
Oluwole OO; Ray MD; Zur RM; Ferrufino CP; Doble B; Patel AR; Bilir SP
Front Immunol; 2024; 15():1393939. PubMed ID: 38855109
[TBL] [Abstract] [Full Text] [Related]
2. Population pharmacokinetics and cd20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-hodgkin lymphoma.
Bender B; Li CC; Marchand M; Turner DC; Li F; Vadhavkar S; Wang B; Deng R; Lu J; Jin J; Li C; Yin S; Wei M; Chanu P
Clin Transl Sci; 2024 Jun; 17(6):e13825. PubMed ID: 38808543
[TBL] [Abstract] [Full Text] [Related]
3. Translational insights into the genetics and immunobiology of relapsed/refractory follicular lymphoma.
Yaniv B; Tanenbaum B; Kazakova V; Patel SA
Leuk Res; 2024 Jul; 142():107519. PubMed ID: 38761562
[TBL] [Abstract] [Full Text] [Related]
4. Long-term Remissions Following cd20-Directed Chimeric Antigen Receptor-Adoptive T-cell Therapy.
Mo G; Lee SY; Coffey DG; Voillet V; Kirsch IR; Gottardo R; Smythe KS; Yeung CCS; Greenbaum A; Green DJ; Maloney DG; Till BG
Blood Cancer Discov; 2024 Jul; 5(4):258-266. PubMed ID: 38747505
[TBL] [Abstract] [Full Text] [Related]
5. Relapse after glofitamab has a poor prognosis and rates of cd20 loss are high.
Grigg S; Minson A; Prins E; Dickinson MJ
Br J Haematol; 2024 Jul; 205(1):122-126. PubMed ID: 38720530
[TBL] [Abstract] [Full Text] [Related]
6. Polatuzumab vedotin, venetoclax, and an anti-cd20 monoclonal antibody in relapsed/refractory B-cell non-hodgkin lymphoma.
Yuen S; Phillips TJ; Bannerji R; Marlton P; Gritti G; Seymour JF; Johnston A; Arthur C; Dodero A; Sharma S; Hirata J; Musick L; Flowers CR
Am J Hematol; 2024 Jul; 99(7):1281-1289. PubMed ID: 38700035
[TBL] [Abstract] [Full Text] [Related]
7. Advancements in the Management of Follicular lymphoma: A Comprehensive Review.
Merryman R; Mehtap Ö; LaCasce A
Turk J Haematol; 2024 May; 41(2):69-82. PubMed ID: 38660754
[TBL] [Abstract] [Full Text] [Related]
8. Mycosis fungoides with large cell transformation (CD30+) and B-cell chronic lymphocytic leukemia.
Petković M; Ilić I; Jurakić Tončić R; Radman-Livaja I; Čeović R
Acta Dermatovenerol Croat; 2023 Dec; 31(4):223-224. PubMed ID: 38651850
[TBL] [Abstract] [Full Text] [Related]
9. Complete response to front-line therapies is associated with long-term survival in HIV-related lymphomas in Taiwan.
Ma WL; Liu WD; Sun HY; Sheng WH; Hsieh SM; Wu SJ; Hung CC
J Microbiol Immunol Infect; 2024 Jun; 57(3):426-436. PubMed ID: 38632022
[TBL] [Abstract] [Full Text] [Related]
10. Efficacy and Nuances of Precision Molecular Engineering for hodgkin's Disease to a Gene Therapeutic Approach.
Qadir MI; Ahmed B; Hussain N
Crit Rev Immunol; 2024; 44(5):41-50. PubMed ID: 38618727
[TBL] [Abstract] [Full Text] [Related]
11. Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-hodgkin lymphoma: An Australasian lymphoma Alliance study.
Manos K; Churilov L; Grigg A; Di Ciaccio P; Wong J; Chandra Sekaran U; Wight J; Goh Z; Jina H; Butler L; Yannakou CK; Hamad N; Gregory GP; Gangatharan S; Cochrane T; Hawkes EA; Lasica M
Br J Haematol; 2024 Jul; 205(1):146-157. PubMed ID: 38485116
[TBL] [Abstract] [Full Text] [Related]
12. Primary extranodal NK/T cell lymphoma of stomach: A case report and review of literature.
Mane P; Ramteke P; Singh A; Gogia A; Mallick S
Indian J Pathol Microbiol; 2024 Apr; 67(2):463-465. PubMed ID: 38391355
[TBL] [Abstract] [Full Text] [Related]
13. The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
Brillembourg H; Martínez-Cibrián N; Bachiller M; Alserawan L; Ortiz-Maldonado V; Guedan S; Delgado J
Br J Haematol; 2024 May; 204(5):1649-1659. PubMed ID: 38362778
[TBL] [Abstract] [Full Text] [Related]
14. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas.
Polgarova K; Trneny M
Expert Opin Biol Ther; 2024; 24(1-2):7-13. PubMed ID: 38305755
[TBL] [Abstract] [Full Text] [Related]
15. High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-hodgkin lymphoma patients treated with R-CHOP.
Dhar S; Chakravarti M; Ganguly N; Saha A; Dasgupta S; Bera S; Sarkar A; Roy K; Das J; Bhuniya A; Ghosh S; Sarkar M; Hajra S; Banerjee S; Pal C; Saha B; Mukherjee KK; Baral R; Bose A
Front Immunol; 2023; 14():1303959. PubMed ID: 38304256
[TBL] [Abstract] [Full Text] [Related]
16. Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell lymphoma: Real-World Data Analysis.
Ip A; Mutebi A; Wang T; Jun M; Kalsekar A; Navarro FR; Wang A; Kamalakar R; Sacchi M; Elliott B
Adv Ther; 2024 Mar; 41(3):1226-1244. PubMed ID: 38302846
[TBL] [Abstract] [Full Text] [Related]
17. Analysis of Notch1 protein expression in methotrexate-associated lymphoproliferative disorders.
Okatani T; Nishimura MF; Egusa Y; Yoshida S; Nishimura Y; Nishikori A; Yoshino T; Yamamoto H; Sato Y
J Clin Exp Hematop; 2024 Mar; 64(1):1-9. PubMed ID: 38281745
[TBL] [Abstract] [Full Text] [Related]
18. Bispecific antibodies in indolent B-cell lymphomas.
Radhakrishnan VS; Davies AJ
Front Immunol; 2023; 14():1295599. PubMed ID: 38274793
[TBL] [Abstract] [Full Text] [Related]
19. Consensus recommendations on the management of toxicity associated with CD3×cd20 bispecific antibody therapy.
Crombie JL; Graff T; Falchi L; Karimi YH; Bannerji R; Nastoupil L; Thieblemont C; Ursu R; Bartlett N; Nachar V; Weiss J; Osterson J; Patel K; Brody J; Abramson JS; Lunning M; Shah NN; Ayed A; Kamdar M; Parsons B; Caimi P; Flinn I; Herrera A; Sharman J; McKenna M; Armand P; Kahl B; Smith S; Zelenetz A; Budde LE; Hutchings M; Phillips T; Dickinson M
Blood; 2024 Apr; 143(16):1565-1575. PubMed ID: 38252906
[TBL] [Abstract] [Full Text] [Related]
20. Primary lymphoma of bone of the little finger: a case report and review of the literature.
Barbon DA; Williams TP; Hulse HB; Hansford BG
Skeletal Radiol; 2024 Aug; 53(8):1645-1650. PubMed ID: 38225403
[TBL] [Abstract] [Full Text] [Related]
[Next]
